"Paclitaxel" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
| Descriptor ID |
D017239
|
| MeSH Number(s) |
D02.455.426.392.368.242.888.777 D02.455.849.291.850.777
|
| Concept/Terms |
Taxol- Taxol
- Taxol A
- Bris Taxol
- Taxol, Bris
|
Below are MeSH descriptors whose meaning is more general than "Paclitaxel".
Below are MeSH descriptors whose meaning is more specific than "Paclitaxel".
This graph shows the total number of publications written about "Paclitaxel" by people in this website by year, and whether "Paclitaxel" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 3 | 0 | 3 |
| 1997 | 3 | 0 | 3 |
| 1998 | 4 | 3 | 7 |
| 1999 | 4 | 2 | 6 |
| 2000 | 2 | 0 | 2 |
| 2001 | 5 | 0 | 5 |
| 2002 | 0 | 1 | 1 |
| 2003 | 5 | 1 | 6 |
| 2004 | 3 | 1 | 4 |
| 2005 | 2 | 3 | 5 |
| 2006 | 4 | 5 | 9 |
| 2007 | 1 | 5 | 6 |
| 2008 | 2 | 9 | 11 |
| 2009 | 0 | 4 | 4 |
| 2010 | 2 | 4 | 6 |
| 2011 | 4 | 7 | 11 |
| 2012 | 2 | 4 | 6 |
| 2013 | 1 | 8 | 9 |
| 2014 | 4 | 4 | 8 |
| 2015 | 4 | 6 | 10 |
| 2016 | 4 | 3 | 7 |
| 2017 | 3 | 11 | 14 |
| 2018 | 4 | 2 | 6 |
| 2019 | 5 | 9 | 14 |
| 2020 | 3 | 4 | 7 |
| 2021 | 2 | 4 | 6 |
| 2022 | 1 | 3 | 4 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Paclitaxel" by people in Profiles.
-
Blocking the functional domain of TIP1 by antibodies sensitizes cancer to radiation therapy. Biomed Pharmacother. 2023 Oct; 166:115341.
-
Accelerated cerebromicrovascular senescence contributes to cognitive decline in a mouse model of paclitaxel (Taxol)-induced chemobrain. Aging Cell. 2023 07; 22(7):e13832.
-
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. J Clin Oncol. 2022 Dec 01; 40(34):3965-3974.
-
Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report. J Med Case Rep. 2022 Oct 05; 16(1):364.
-
MARK2 regulates chemotherapeutic responses through class IIa HDAC-YAP axis in pancreatic cancer. Oncogene. 2022 07; 41(31):3859-3875.
-
Pancreatic Ductal Cell-Derived Extracellular Vesicles Are Effective Drug Carriers to Enhance Paclitaxel's Efficacy in Pancreatic Cancer Cells through Clathrin-Mediated Endocytosis. Int J Mol Sci. 2022 Apr 26; 23(9).
-
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2022 02; 164(2):398-405.
-
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study. Clin Cancer Res. 2022 01 01; 28(1):36-44.
-
Selective and Marked Blockade of Endothelial Sprouting Behavior Using Paclitaxel and Related Pharmacologic Agents. Am J Pathol. 2021 12; 191(12):2245-2264.
-
ABCB1 Does Not Require the Side-Chain Hydrogen-Bond Donors Gln347, Gln725, Gln990 to Confer Cellular Resistance to the Anticancer Drug Taxol. Int J Mol Sci. 2021 Aug 09; 22(16).